Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

NCT06141031 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: TTI-101
RADIATION: Stereotactic body radiation therapy

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]